AI-powered voice screening for COVID earns CE mark

Dave Pearson | | Health Exec | Economics
Voice Recognition Smartphone

Photo by Ekaterina Bolovtsova via Pexels

An Israeli AI startup has been cleared to market COVID-detecting voice analysis software in Europe, according to No Camels.

Vocalis Health announced the CE mark win Feb. 17, saying its VocalisCheck product can be accessed by smartphones and is intended to serve as an initial screening tool, not a definitive diagnostic tester.

The company says the system achieved good accuracy, 81%, in a recent clinical trial involving more than 2,000 people in India. The participants represented speakers of at least four languages.

Vocalis is working with Mayo Clinic on refining the software and expanding its applications for voice-based health screening.

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

HHS employees offered two months of pay to quit their jobs
Walgreens $10B private equity buyout financed by 83% debt
Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.